Wilson Sonsini Goodrich & Rosati, P.C. is a U.S.-based law firm that provides corporate, transactional, regulatory, and litigation services to technology, life sciences, and growth enterprises, as well as their investors. Headquartered in California, the firm advises on mergers and acquisitions, capital markets, venture financing, corporate governance, antitrust/competition, intellectual property strategy and licensing, and regulatory matters, including FDA and privacy.
For companies across the pharmaceuticals, biotechnology, and chemicals value chain, Wilson Sonsini supports R&D-to-market activities such as structuring collaborations, protecting and commercializing IP, navigating competition and securities rules, and managing disputes. The firm also counsels on climate, clean energy, and related compliance issues relevant to chemicals and advanced materials, and represents private equity and venture capital investors active in these sectors.
FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.
Ventyx's small molecule pipeline targets chronic inflammation in cardiometabolic, neurodegenerative, and inflammatory diseases, aiming for improved efficacy and safety.
